Rockefeller Capital Management L.P. Reduces Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Rockefeller Capital Management L.P. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 23.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 288,103 shares of the medical research company’s stock after selling 86,910 shares during the period. Rockefeller Capital Management L.P. owned about 0.16% of IQVIA worth $56,622,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Toronto Dominion Bank grew its holdings in IQVIA by 11.3% during the 3rd quarter. Toronto Dominion Bank now owns 60,416 shares of the medical research company’s stock valued at $14,317,000 after buying an additional 6,149 shares during the last quarter. TD Private Client Wealth LLC increased its position in IQVIA by 8.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,031 shares of the medical research company’s stock worth $244,000 after purchasing an additional 80 shares in the last quarter. Sanctuary Advisors LLC increased its position in IQVIA by 60.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 5,498 shares of the medical research company’s stock worth $1,303,000 after purchasing an additional 2,079 shares in the last quarter. World Investment Advisors LLC purchased a new position in IQVIA in the 3rd quarter valued at about $14,633,000. Finally, Arvest Bank Trust Division acquired a new stake in shares of IQVIA during the 3rd quarter worth about $21,079,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Morgan Stanley upped their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Truist Financial dropped their target price on IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a research note on Thursday. JPMorgan Chase & Co. lowered their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, Citigroup cut their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.50.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $145.40 on Friday. The company has a market cap of $25.64 billion, a P/E ratio of 19.39, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The business’s 50-day simple moving average is $182.32 and its 200 day simple moving average is $199.64. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.